Profile data is unavailable for this security.
About the company
Morphic Holding, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing a pipeline of potentially oral small molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Company’s Morphic integrin technology platform (MInT Platform) helps to develop product candidates designed to achieve the potency, high selectivity and pharmaceutical properties required for oral administration. The Company is advancing its pipeline, including its lead product candidate, MORF-057, an orally administered a4b7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease (IBD). It has also developed avb6-specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications.
- Revenue in USD (TTM)0.00
- Net income in USD-179.83m
- Incorporated2014
- Employees128.00
- LocationMorphic Holding Inc35 GATEHOUSE DRIVE A2WALTHAM 02451United StatesUSA
- Phone+1 (781) 996-0955
- Fax+1 (302) 655-5049
- Websitehttps://morphictx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intellia Therapeutics Inc | 52.60m | -485.50m | 2.56bn | 526.00 | -- | 2.46 | -- | 48.60 | -5.37 | -5.37 | 0.5827 | 10.76 | 0.0393 | -- | 2.55 | 100,007.60 | -36.27 | -31.34 | -39.21 | -34.53 | -- | -- | -922.94 | -654.71 | -- | -- | 0.00 | -- | -30.40 | 3.57 | -1.48 | -- | 17.08 | -- |
| Iovance Biotherapeutics Inc | 1.90m | -449.64m | 2.59bn | 557.00 | -- | 3.81 | -- | 1,359.48 | -1.82 | -1.82 | 0.0077 | 2.43 | 0.0023 | -- | -- | 3,418.31 | -53.07 | -51.47 | -59.00 | -57.56 | -846.22 | -- | -23,615.70 | -137,873.80 | 4.42 | -- | 0.0015 | -- | -- | -- | -12.16 | -- | 79.44 | -- |
| PTC Therapeutics, Inc. | 927.56m | -579.22m | 2.61bn | 988.00 | -- | -- | -- | 2.82 | -7.69 | -7.69 | 12.28 | -11.66 | 0.5459 | 2.33 | 4.64 | 938,823.90 | -34.09 | -26.71 | -48.63 | -33.46 | 92.88 | 93.94 | -62.45 | -83.80 | 1.98 | -0.8357 | 1.72 | -- | 34.20 | 28.78 | -12.09 | -- | 32.00 | -- |
| Beam Therapeutics Inc | 360.91m | -134.74m | 2.73bn | 436.00 | -- | 2.99 | -- | 7.56 | -1.74 | -1.74 | 4.54 | 11.10 | 0.2681 | -- | -- | 827,777.50 | -10.01 | -24.54 | -11.79 | -29.26 | -- | -- | -37.33 | -211.96 | -- | -- | 0.00 | -- | 520.01 | -- | 54.16 | -- | 20.78 | -- |
| Agios Pharmaceuticals Inc | 29.40m | -352.62m | 2.73bn | 383.00 | -- | 3.67 | -- | 92.78 | -6.31 | -6.31 | 0.5257 | 13.11 | 0.0294 | 0.1715 | 11.24 | 76,770.23 | -35.24 | -29.54 | -37.04 | -31.88 | 89.95 | -- | -1,199.26 | -3,826.10 | 12.39 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
| Kymera Therapeutics Inc | 79.41m | -154.59m | 2.73bn | 186.00 | -- | 3.84 | -- | 34.41 | -2.50 | -2.50 | 1.29 | 11.59 | 0.1072 | -- | 29.69 | 424,668.40 | -20.86 | -23.03 | -22.67 | -27.64 | -- | -- | -194.67 | -207.82 | -- | -- | 0.0032 | -- | 67.84 | -- | 5.07 | -- | 91.01 | -- |
| Geron Corp | 520.00k | -201.40m | 2.76bn | 141.00 | -- | 7.93 | -- | 5,315.38 | -0.3464 | -0.3464 | 0.0009 | 0.5876 | 0.0012 | -- | 0.3225 | 3,687.94 | -44.41 | -51.32 | -54.44 | -64.90 | -- | -- | -38,729.81 | -19,949.13 | -- | -- | 0.1935 | -- | -60.23 | -25.97 | -29.76 | -- | 120.29 | -- |
| SpringWorks Therapeutics Inc | 26.45m | -339.07m | 2.82bn | 305.00 | -- | 4.96 | -- | 106.54 | -5.15 | -5.15 | 0.4007 | 7.66 | 0.0432 | -- | -- | 86,731.15 | -55.31 | -36.97 | -60.58 | -39.49 | 93.86 | -- | -1,281.78 | -2,176.46 | 6.77 | -- | 0.00 | -- | -- | -- | -17.19 | -- | 90.68 | -- |
| Morphic Holding Inc | 0.00 | -179.83m | 2.84bn | 128.00 | -- | 4.58 | -- | -- | -3.72 | -3.72 | 0.00 | 12.34 | 0.00 | -- | -- | 0.00 | -25.79 | -22.69 | -26.63 | -24.99 | -- | -- | -- | -258.10 | -- | -- | 0.00 | -- | -99.26 | -31.11 | -157.61 | -- | 13.50 | -- |
| MoonLake Immunotherapeutics | 0.00 | -40.68m | 2.86bn | 50.00 | -- | 5.19 | -- | -- | -0.7501 | -0.7501 | 0.00 | 8.63 | 0.00 | -- | -- | 0.00 | -14.53 | -- | -15.60 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
| Apogee Therapeutics Inc | 0.00 | -103.55m | 2.92bn | 91.00 | -- | 3.51 | -- | -- | -2.04 | -2.04 | 0.00 | 14.22 | 0.00 | -- | -- | 0.00 | -21.45 | -- | -22.20 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
| Celldex Therapeutics, Inc. | 6.07m | -144.88m | 2.94bn | 160.00 | -- | 3.50 | -- | 483.69 | -2.84 | -2.84 | 0.1182 | 12.72 | 0.0102 | -- | 3.05 | 37,950.00 | -24.28 | -29.65 | -25.16 | -31.42 | -- | -- | -2,385.97 | -1,747.94 | -- | -- | 0.00 | -- | 192.02 | -6.32 | -25.91 | -- | 17.46 | -- |
| Rhythm Pharmaceuticals Inc | 91.93m | -273.87m | 2.99bn | 226.00 | -- | 48.56 | -- | 32.53 | -4.62 | -4.62 | 1.57 | 1.01 | 0.3042 | 1.53 | 8.06 | 406,747.80 | -90.64 | -47.21 | -108.65 | -52.84 | 88.37 | -- | -297.93 | -681.38 | 4.20 | -139.42 | 0.6355 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
| Amicus Therapeutics, Inc. | 423.49m | -147.07m | 3.02bn | 517.00 | -- | 23.07 | -- | 7.12 | -0.493 | -0.493 | 1.42 | 0.4413 | 0.5955 | 1.00 | 5.86 | 819,127.70 | -20.68 | -30.65 | -25.76 | -36.55 | 89.62 | 88.94 | -34.73 | -86.10 | 2.61 | -1.36 | 0.7482 | -- | 21.30 | 34.35 | 35.92 | -- | 3.36 | -- |
Data as of Jul 26 2024. Currency figures normalised to Morphic Holding Inc's reporting currency: US Dollar USD
68.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 7.51m | 14.98% |
| Wellington Management Co. LLPas of 28 Jun 2024 | 5.81m | 11.61% |
| Point72 Asset Management LPas of 31 Mar 2024 | 4.69m | 9.36% |
| EcoR1 Capital, LLCas of 23 Apr 2024 | 3.01m | 6.02% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.77m | 5.53% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.67m | 5.32% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 2.47m | 4.93% |
| Invus Public Equities Advisors LLCas of 31 Mar 2024 | 2.21m | 4.42% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 2.17m | 4.33% |
| Pictet Asset Management SAas of 31 Mar 2024 | 1.19m | 2.37% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
